Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab

被引：16
作者：
Liu, Chun-Yu [1 ,2 ]
Teng, Hao-Wei [1 ,2 ]
Lirng, Jiing-Feng [2 ]
Chiou, Tzeon-Jye [2 ,3 ]
Chen, Po-Min [1 ,2 ]
Hsiao, Liang-Tsai [1 ,2 ]
机构：
[1] Taipei Vet Gen Hosp, Div Hematol & Oncol, Dept Med, Taipei 112, Taiwan
[2] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan
[3] Taipei Vet Gen Hosp, Div Transfus Med, Dept Med, Taipei 112, Taiwan
来源：
LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 10期
关键词：
D O I：
10.1080/10428190802311375
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2018 / 2021
页数：4
相关论文
共 15 条
[1]   Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma [J].
Antonini, Giovanni ;
Cox, Maria Cristina ;
Montefusco, Enrico ;
Ferrari, Antonella ;
Conte, Esmeralda ;
Morino, Stefania ;
Latino, Pamela ;
Trasimeni, Guido ;
Monarca, Bruno .
JOURNAL OF NEURO-ONCOLOGY, 2007, 81 (02) :197-199
[2]   Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up [J].
Bjoerkholm, M. ;
Hagberg, H. ;
Holte, H. ;
Kvaloy, S. ;
Teerenhovi, L. ;
Anderson, H. ;
Cavallin-Stahl, E. ;
Myhre, J. ;
Pertovaara, H. ;
Oest, A. ;
Nilsson, B. ;
Oesby, E. .
ANNALS OF ONCOLOGY, 2007, 18 (06) :1085-1089
[3]   Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) [J].
Boehme, V. ;
Zeynalova, S. ;
Kloess, M. ;
Loeffler, M. ;
Kaiser, U. ;
Pfreundschuh, M. ;
Schmitz, N. .
ANNALS OF ONCOLOGY, 2007, 18 (01) :149-157
[4]   Central nervous system relapse of systemic non-Hodgkin's lymphoma: Results of treatment based on high-dose methotrexate combination chemotherapy [J].
Bokstein, F ;
Lossos, A ;
Lossos, IS ;
Siegal, T .
LEUKEMIA & LYMPHOMA, 2002, 43 (03) :587-593
[5]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[6]   Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab [J].
Feugier, P ;
Virion, JM ;
Tilly, H ;
Haioun, C ;
Marit, G ;
Macro, M ;
Bordessoule, D ;
Recher, C ;
Blanc, M ;
Molina, T ;
Lederlin, P ;
Coiffier, B .
ANNALS OF ONCOLOGY, 2004, 15 (01) :129-133
[7]   Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis [J].
Hollender, A ;
Kvaloy, S ;
Lote, K ;
Nome, O ;
Holte, H .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (14) :1762-1768
[8]   Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system [J].
Jahnke, K ;
Thiel, E ;
Martus, P ;
Schwartz, S ;
Korfel, A .
ANNALS OF HEMATOLOGY, 2006, 85 (01) :45-50
[9]   Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab [J].
Pels, H ;
Schulz, H ;
Manzke, O ;
Hom, E ;
Thall, A ;
Engert, A .
JOURNAL OF NEURO-ONCOLOGY, 2002, 59 (03) :213-216
[10]   Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: Experience with two cases and review of the literature [J].
Pels, H ;
Schulz, H ;
Schlegel, U ;
Engert, A .
ONKOLOGIE, 2003, 26 (04) :351-354
12